Treatment Results of Malignant Lymphoma of Nasopharynx at National Taiwan University Hospital

貢獻的翻譯標題: 臺大醫院惡性鼻咽淋巴瘤之治療成果

雷 德, 許 維中, 鍾 娜娜, 王 博民, 丁 禮莉(Lai-Lei Ting), 洪 瑞隆

研究成果: 雜誌貢獻文章

摘要

目的:回顧過去十五年(1977-1993)在臺大醫院惡性鼻咽淋巴瘤之治療成果。材料與方法:這十五年中臺大醫院共有40位惡性鼻咽淋巴瘤之病患。年齡分佈自13至81歲,男、女性病患各20位。第一、二期各有18及22個病例。以組織病理學而言,低 、中、高級各有10、26及4位。7位病患只接受放射治療,15位病息只接受化學治療,10位病患接受放射及化學合併治療,8位病患未接受任何治療。結果:第一二期五年存活率分別為65.7%及2.73%。以Rappaport分類法時,結節性與瀰漫性五年存活率分別為 72.7%及33.5%;以working formulation分類時,低、中、高級五年存活率分別為80.0%,39.0%及50.0%。放射治療,化學治療及合併療法之五年存活率分別為100.0%,58.7%及30.0%。結論:淋巴瘤局限於鼻咽之淋巴瘤可用放射治療加以控制。以組織病理學分類時,低級或結節性之惡性鼻咽淋巴瘤可單獨使用放射治療。而中級或瀰漫性之惡性鼻咽淋巴瘤使用化學治療或合併療法,對病患之存活率則有所俾益。
原文英語
頁(從 - 到)85-91
頁數7
期刊放射治療與腫瘤學
4
發行號2
DOIs
出版狀態已發佈 - 1997
對外發佈Yes

指紋

Nasopharynx
Taiwan
Lymphoma
Therapeutics
Radiotherapy
Survival Rate
Drug Therapy
Adjuvant Radiotherapy

Keywords

  • Nasopharynx
  • Lymphoma
  • neoplasm
  • Radiotherapy
  • Five-year survival rate

引用此文

Treatment Results of Malignant Lymphoma of Nasopharynx at National Taiwan University Hospital. / 雷德; 許維中; 鍾娜娜; 王博民; 丁禮莉(Lai-Lei Ting); 洪瑞隆.

於: 放射治療與腫瘤學, 卷 4, 編號 2, 1997, p. 85-91.

研究成果: 雜誌貢獻文章

雷德 ; 許維中 ; 鍾娜娜 ; 王博民 ; 丁禮莉(Lai-Lei Ting) ; 洪瑞隆. / Treatment Results of Malignant Lymphoma of Nasopharynx at National Taiwan University Hospital. 於: 放射治療與腫瘤學. 1997 ; 卷 4, 編號 2. 頁 85-91.
@article{3f64ea5c86e84a5ba6af557a8e798d1e,
title = "Treatment Results of Malignant Lymphoma of Nasopharynx at National Taiwan University Hospital",
abstract = "Purpose: To evaluate the therapeutic results of nasopharyngeal malignant lymphoma treated at NTUH over the past fifteen years (1979-1993). Materials & Methods: Forty patients with malignant lymphoma of nasopharynx visited our hospital in the past fifteen years and their data were analyzed. The age of the patients ranged from 13 to 81 years old. There were 20 male patients and 20 female patients. Stage I and LI patients were 18 and 22, respectively. According to histopathologic classification, patients with low grade, intermediate grade and high grade malignant lymphoma were 10, 26 and 4, respectively. Seven patients received radical radiotherapy and 15 patients received chemotherapy. The remaining 10 patients were treated by combined chemotherapy and irradiation. Eight patients did not receive any treatment. Results: The actuarial five-year survival rates for nasopharyngeal malignant lymphoma patients with Stage I, II were 65.7{\%} and 27.3{\%}, respectively. When classified by the Rappaport classification, the actuarial five-year survival rates for patients of nodular type and diffuse type were 72.7{\%} and 33.5{\%}, respectively. The actuarial five-year survival rates for patients of Low grade, intermediate grade and high grade nasopharyngeal malignant lymphoma were 80.0{\%}, 39.0{\%}, and 50.0{\%}, respectively. The actuarial five- year survival rates for patients treated with radiotherapy, chemotherapy and combined treatment modalities were 100.0{\%}, 58.7{\%}, and 30.0{\%}, respectively.Conclusion: Lymphoma clinically localized to nasopharynx can be cured by radiotherapy. When classified by histopathology, patients with low grade or nodular type can be successfully treated using local radiotherapy alone. Chemotherapy used as primary treatment (with or without adjuvant radiotherapy) may be benefit for intermediate grade or diffuse type patients.",
keywords = "鼻咽, 淋巴瘤, 腫瘤, 放射治療, 五年存活率, Nasopharynx, Lymphoma, Neoplasm, Radiotherapy, Five-year survival rate, Nasopharynx, Lymphoma, neoplasm, Radiotherapy, Five-year survival rate",
author = "德 雷 and 維中 許 and 娜娜 鍾 and 博民 王 and 丁, {禮莉(Lai-Lei Ting)} and 瑞隆 洪",
year = "1997",
doi = "10.6316/TRO/199704",
language = "English",
volume = "4",
pages = "85--91",
journal = "放射治療與腫瘤學",
issn = "1023-988x",
publisher = "台灣放射腫瘤學會",
number = "2",

}

TY - JOUR

T1 - Treatment Results of Malignant Lymphoma of Nasopharynx at National Taiwan University Hospital

AU - 雷, 德

AU - 許, 維中

AU - 鍾, 娜娜

AU - 王, 博民

AU - 丁, 禮莉(Lai-Lei Ting)

AU - 洪, 瑞隆

PY - 1997

Y1 - 1997

N2 - Purpose: To evaluate the therapeutic results of nasopharyngeal malignant lymphoma treated at NTUH over the past fifteen years (1979-1993). Materials & Methods: Forty patients with malignant lymphoma of nasopharynx visited our hospital in the past fifteen years and their data were analyzed. The age of the patients ranged from 13 to 81 years old. There were 20 male patients and 20 female patients. Stage I and LI patients were 18 and 22, respectively. According to histopathologic classification, patients with low grade, intermediate grade and high grade malignant lymphoma were 10, 26 and 4, respectively. Seven patients received radical radiotherapy and 15 patients received chemotherapy. The remaining 10 patients were treated by combined chemotherapy and irradiation. Eight patients did not receive any treatment. Results: The actuarial five-year survival rates for nasopharyngeal malignant lymphoma patients with Stage I, II were 65.7% and 27.3%, respectively. When classified by the Rappaport classification, the actuarial five-year survival rates for patients of nodular type and diffuse type were 72.7% and 33.5%, respectively. The actuarial five-year survival rates for patients of Low grade, intermediate grade and high grade nasopharyngeal malignant lymphoma were 80.0%, 39.0%, and 50.0%, respectively. The actuarial five- year survival rates for patients treated with radiotherapy, chemotherapy and combined treatment modalities were 100.0%, 58.7%, and 30.0%, respectively.Conclusion: Lymphoma clinically localized to nasopharynx can be cured by radiotherapy. When classified by histopathology, patients with low grade or nodular type can be successfully treated using local radiotherapy alone. Chemotherapy used as primary treatment (with or without adjuvant radiotherapy) may be benefit for intermediate grade or diffuse type patients.

AB - Purpose: To evaluate the therapeutic results of nasopharyngeal malignant lymphoma treated at NTUH over the past fifteen years (1979-1993). Materials & Methods: Forty patients with malignant lymphoma of nasopharynx visited our hospital in the past fifteen years and their data were analyzed. The age of the patients ranged from 13 to 81 years old. There were 20 male patients and 20 female patients. Stage I and LI patients were 18 and 22, respectively. According to histopathologic classification, patients with low grade, intermediate grade and high grade malignant lymphoma were 10, 26 and 4, respectively. Seven patients received radical radiotherapy and 15 patients received chemotherapy. The remaining 10 patients were treated by combined chemotherapy and irradiation. Eight patients did not receive any treatment. Results: The actuarial five-year survival rates for nasopharyngeal malignant lymphoma patients with Stage I, II were 65.7% and 27.3%, respectively. When classified by the Rappaport classification, the actuarial five-year survival rates for patients of nodular type and diffuse type were 72.7% and 33.5%, respectively. The actuarial five-year survival rates for patients of Low grade, intermediate grade and high grade nasopharyngeal malignant lymphoma were 80.0%, 39.0%, and 50.0%, respectively. The actuarial five- year survival rates for patients treated with radiotherapy, chemotherapy and combined treatment modalities were 100.0%, 58.7%, and 30.0%, respectively.Conclusion: Lymphoma clinically localized to nasopharynx can be cured by radiotherapy. When classified by histopathology, patients with low grade or nodular type can be successfully treated using local radiotherapy alone. Chemotherapy used as primary treatment (with or without adjuvant radiotherapy) may be benefit for intermediate grade or diffuse type patients.

KW - 鼻咽

KW - 淋巴瘤

KW - 腫瘤

KW - 放射治療

KW - 五年存活率

KW - Nasopharynx

KW - Lymphoma

KW - Neoplasm

KW - Radiotherapy

KW - Five-year survival rate

KW - Nasopharynx

KW - Lymphoma

KW - neoplasm

KW - Radiotherapy

KW - Five-year survival rate

UR - http://www.airitilibrary.com/Publication/alDetailedMesh?DocID=1023988x-199706-4-2-85-91-a

U2 - 10.6316/TRO/199704

DO - 10.6316/TRO/199704

M3 - Article

VL - 4

SP - 85

EP - 91

JO - 放射治療與腫瘤學

JF - 放射治療與腫瘤學

SN - 1023-988x

IS - 2

ER -